Israel's Healthcare Crisis: When Protekzia Fails, Patients Pay the Price

Uncovering a Crisis in Coverage

When Israel's Health Minister finally intervened to address the denial of Protekzia coverage for a young patient, it was more than a bureaucratic hiccup—it was a stark reminder of how fragile our healthcare system truly is. For years, Protekzia has been a critical treatment for severe atopic dermatitis, yet many patients, especially children, have been denied access due to insurance limitations and red tape. This isn't just a case of denial; it's a reflection of how systemic inefficiencies can turn medical necessity into a battlefield of bureaucratic politics.

What Is Protekzia?

Protekzia is a biologic medication that targets the immune system's overreaction in patients with severe atopic dermatitis. It's a game-changer for children and adults who suffer from chronic, unmanageable skin conditions that don't respond to traditional therapies. For many, it's the only hope of living a life free from constant itching, pain, and emotional distress.

"This is not just about a drug—it's about a child's ability to sleep, to go to school, to live normally," said Dr. Sarah Goldstein, a pediatric dermatologist in Tel Aviv who has treated dozens of children with Protekzia.

The drug, developed by AbbVie, is not cheap. Its price tag often exceeds $30,000 per year, which makes its coverage decisions a point of contention for insurance providers and the Ministry of Health alike. But in a system where health should be a right—not a privilege—denying access based on cost alone raises serious ethical questions.

The Systemic Flaw

Israel's healthcare model, while generally robust compared to many nations, is plagued by gaps that leave vulnerable populations exposed. The Ministry of Health's approach to coverage decisions often relies heavily on cost-effectiveness analyses, which may not fully account for the real-life impact of chronic illness. When a child with severe eczema can't access Protekzia, the consequences are not just medical—they're social and psychological.

We've seen how delays in treatment can lead to worsening conditions, increased hospitalization rates, and even long-term developmental impacts on children's mental health. The Ministry's failure to act sooner in these cases shows a troubling lack of accountability and compassion.

What the Minister's Intervention Really Means

The Health Minister's recent move to intervene in individual cases is a step, but not nearly enough. It's reactive, not proactive. It addresses symptoms rather than root causes. The intervention may help one child or family, but it does nothing to fix a system that routinely fails to prioritize patients' needs over cost considerations.

In the past, such interventions have been rare and often criticized for being too little, too late. We need consistent policies and frameworks that ensure no patient is denied access to life-changing treatments simply because their insurance company can't or won't cover them. That's not just a policy failure—it's a moral one.

Who's Really Paying the Price?

When Protekzia is denied, the burden doesn't fall solely on patients and families. It cascades through society. Parents miss work. Children fall behind in school. Doctors are caught between ethical obligations and insurance restrictions. And the Ministry of Health is left with the unenviable task of defending a system that many feel is broken.

This isn't just an Israeli problem—it's a global one. In countries like the U.S., Canada, and Germany, similar challenges exist with biologics and other high-cost treatments. But what sets Israel apart is not the existence of these issues, but how quickly they're ignored until public outrage forces action.

A Call for Reform

What's needed now is more than a ministerial intervention. We need structural reform—transparent policies that prioritize patient welfare over corporate or administrative cost-saving measures. This means:

• Establishing clear, science-based pathways for coverage decisions
• Increasing transparency in how treatment decisions are made
• Creating a dedicated ombudsman office to help families navigate healthcare disputes
• Ensuring that financial toxicity doesn't prevent access to effective treatments

We must ask ourselves: Is this the kind of society we want to live in, where the most vulnerable among us are denied care simply because they can't pay? This is not a political issue—it's a humanitarian one. It's time for real change.

Conclusion

The story of Protekzia and the Israeli Ministry of Health reveals more than just an insurance denial—it shows how deeply entrenched inefficiencies and lack of accountability can lead to human suffering. When health is treated as a commodity, it becomes clear that we're not just failing patients—we're failing our own humanity.

As we move forward, the question isn't whether we can afford to act. It's whether we have the courage to do so.